Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537482 · ClinicalTrials.gov registry record · Early Phase 1
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
A Early Phase 1 study of Hematologic Malignancies, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT03537482: Recruiting Early Phase 1 study of Hematologic Malignancies, sponsored by Ascentage Pharma Group.
NCT03537482 is a Early Phase 1 study of Hematologic Malignancies that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 90 participants, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03537482, a Early Phase 1 study of Hematologic Malignancies, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Conditions Studied
Interventions
- DRUG APG-2575
Study Locations (5)
Victoria
- St. Vincent Hospital - Fitzroy
- Epworth Healthcare - Richmond
Florida
- Mayo Clinic - Jacksonville
North Carolina
- Duke Unviersity - Durham
Texas
- MDACC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2025-02-15 |
| Phase | Early Phase 1 |
What NCT03537482 shows while recruiting
NCT03537482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which APG-2575 is the first listed.
NCT03537482 lists 5 locations in 4 states (Victoria, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT03537482 about?
NCT03537482 is a clinical study titled "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies". This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
What is the current status of trial NCT03537482?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2018-08-07. Estimated completion is 2025-02-15.
What conditions does trial NCT03537482 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT03537482?
The interventions under investigation include: APG-2575 (DRUG).
Who is sponsoring clinical trial NCT03537482?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03537482 being conducted?
This trial has 5 study locations across Florida, North Carolina, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03537482's enrollment target sits among peer trials
90 18th of 45 higher than 28 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI